AU2020231934B2 - Compounds useful in HIV therapy - Google Patents

Compounds useful in HIV therapy Download PDF

Info

Publication number
AU2020231934B2
AU2020231934B2 AU2020231934A AU2020231934A AU2020231934B2 AU 2020231934 B2 AU2020231934 B2 AU 2020231934B2 AU 2020231934 A AU2020231934 A AU 2020231934A AU 2020231934 A AU2020231934 A AU 2020231934A AU 2020231934 B2 AU2020231934 B2 AU 2020231934B2
Authority
AU
Australia
Prior art keywords
mmol
fluoro
purin
amino
ethynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2020231934A
Other languages
English (en)
Other versions
AU2020231934A8 (en
AU2020231934A1 (en
Inventor
Martha Alicia De La Rosa
John F. Miller
B. Narasimhulu Naidu
Vicente Samano
David Temelkoff
Emile Johann Velthuisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
ViiV Healthcare Co
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69845479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020231934(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd, ViiV Healthcare Co filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of AU2020231934A1 publication Critical patent/AU2020231934A1/en
Publication of AU2020231934A8 publication Critical patent/AU2020231934A8/en
Application granted granted Critical
Publication of AU2020231934B2 publication Critical patent/AU2020231934B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020231934A 2019-03-06 2020-03-04 Compounds useful in HIV therapy Ceased AU2020231934B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
US62/814,316 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (3)

Publication Number Publication Date
AU2020231934A1 AU2020231934A1 (en) 2021-09-23
AU2020231934A8 AU2020231934A8 (en) 2022-03-24
AU2020231934B2 true AU2020231934B2 (en) 2023-04-20

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020231934A Ceased AU2020231934B2 (en) 2019-03-06 2020-03-04 Compounds useful in HIV therapy

Country Status (22)

Country Link
US (4) US12240853B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934760A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022525013A (cg-RX-API-DMAC7.html)
KR (1) KR20210136052A (cg-RX-API-DMAC7.html)
CN (1) CN113811360A (cg-RX-API-DMAC7.html)
AR (1) AR118240A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020231934B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017604A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132112A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002309A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021012579A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210460A (cg-RX-API-DMAC7.html)
EA (1) EA202192433A1 (cg-RX-API-DMAC7.html)
IL (1) IL285894A (cg-RX-API-DMAC7.html)
MA (1) MA55200A (cg-RX-API-DMAC7.html)
MX (1) MX2021010700A (cg-RX-API-DMAC7.html)
PE (1) PE20212089A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021500034A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109253SA (cg-RX-API-DMAC7.html)
TW (1) TW202102233A (cg-RX-API-DMAC7.html)
WO (1) WO2020178767A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202106096B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
KR102987126B1 (ko) * 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
CN116370479B (zh) * 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
AU2022211056A1 (en) * 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) * 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
WO2022182604A1 (en) * 2021-02-23 2022-09-01 Viiv Healthcare Company Compounds useful in hiv treatment
EP4658663A2 (en) * 2023-01-30 2025-12-10 Merck Sharp & Dohme LLC Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589026A1 (en) * 2004-03-24 2005-10-26 Yamasa Corporation 4'-C-Substituted-2-Haloadenosine derivative
WO2015148746A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
WO2016066283A1 (en) * 2014-10-31 2016-05-06 Sandoz Ag Improved fluorination process
WO2017053216A2 (en) * 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE60005502T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-purin-nukleoside
WO2002074769A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
UY34372A (es) 2011-10-06 2013-05-31 Dow Agrosciences Llc Moléculas de ácido nucleico que se dirigen a rpa70 y confieren resistencia a plagas de coleópteros.
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
SI2827875T1 (sl) 2012-03-21 2019-04-30 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2952714T3 (es) 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
CN105829333A (zh) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
US9603864B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201610597QA (en) 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP7160466B2 (ja) 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
WO2018085307A1 (en) 2016-11-03 2018-05-11 Wu Laurence I Prodrugs of clofarabine
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
CA3096400A1 (en) 2018-04-09 2019-10-17 Eisai R&D Management Co., Ltd. Certain pladienolide compounds and methods of use
MA53280A (fr) 2018-08-09 2021-11-17 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US20210323993A1 (en) 2018-08-30 2021-10-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
US12018435B2 (en) 2019-03-06 2024-06-25 Chemstone, Inc. Liquid dispersions for acyl halides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589026A1 (en) * 2004-03-24 2005-10-26 Yamasa Corporation 4'-C-Substituted-2-Haloadenosine derivative
WO2015148746A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
WO2016066283A1 (en) * 2014-10-31 2016-05-06 Sandoz Ag Improved fluorination process
WO2017053216A2 (en) * 2015-09-23 2017-03-30 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BANERJEE, S., ET AL. "Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications" Journal of Drug Delivery (2012): 1-17 *
IRBY, D., ET AL. "Lipid-Drug Conjugate for Enhancing Drug Delivery" Molecular Pharmaceutics (2017) 14:1325-1338 *

Also Published As

Publication number Publication date
PE20212089A1 (es) 2021-11-04
US20260035371A1 (en) 2026-02-05
TW202102233A (zh) 2021-01-16
CO2021012579A2 (es) 2021-10-20
BR112021017604A2 (pt) 2021-11-16
EP3934760A1 (en) 2022-01-12
ZA202106096B (en) 2023-03-29
US12240853B2 (en) 2025-03-04
EA202192433A1 (ru) 2021-12-28
US20230174534A1 (en) 2023-06-08
US20220411425A1 (en) 2022-12-29
CR20210460A (es) 2022-02-03
WO2020178767A1 (en) 2020-09-10
MX2021010700A (es) 2021-10-01
CA3132112A1 (en) 2020-09-10
PH12021500034A1 (en) 2022-06-06
KR20210136052A (ko) 2021-11-16
SG11202109253SA (en) 2021-09-29
AU2020231934A8 (en) 2022-03-24
AU2020231934A1 (en) 2021-09-23
IL285894A (en) 2021-10-31
AR118240A1 (es) 2021-09-22
US20240182473A1 (en) 2024-06-06
MA55200A (fr) 2022-01-12
JP2022525013A (ja) 2022-05-11
CL2021002309A1 (es) 2022-09-20
CN113811360A (zh) 2021-12-17

Similar Documents

Publication Publication Date Title
US20260035371A1 (en) Compounds useful in hiv therapy
AU2012352110B2 (en) Derivatives of betulin
EP2791102B1 (en) Propenoate derivatives of betulin
US20110218204A1 (en) Pharmaceutically acceptable salts of novel betulinic acid derivatives
EP3844164A1 (en) Compounds useful in hiv therapy
EP3833437A1 (en) Compounds useful in hiv therapy
EP4021916A1 (en) 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
WO2019171285A1 (en) Compounds useful in hiv therapy
US20140221328A1 (en) Pharmaceutically acceptable salts of novel betulinic acid derivatives
CA3202957A1 (en) Substituted pyridotriazine compounds and uses thereof
US20230151049A1 (en) Compounds Useful in HIV Therapy
WO2013091144A1 (en) Propenoate derivatives of betulin
JP2022520384A (ja) Hiv阻害剤としての新規トリテルペン誘導体
EP4010349A1 (en) 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 35 , NO 38 , PAGE(S) 7559 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAMES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED; VIIV HEALTHCARE COMPANY , APPLICATION NO. 2020231934, UNDER INID (71) CORRECT THE APPLICANT NAME TO GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED; AND UNDER INID (72) CORRECT THE CO-INVENTOR TO NAIDU, B. NARASIMHULU

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired